Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

642
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
642

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy.

JAMA neurology·2026
Same author

The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Genome-wide association analysis provides insights into the molecular etiology of dilated cardiomyopathy.

Nature genetics·2024
Same author

CATH v4.4: major expansion of CATH by experimental and predicted structural data.

Nucleic acids research·2024
Same author

Implementation of a Standardized Process of Coude Catheter Insertion Decreases Traumatic Catheterizations.

Urology·2024

Related Experiment Video

Updated: May 5, 2026

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
08:05

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

Published on: March 1, 2017

8.8K

Natalizumab: bench to bedside and beyond.

Richard Rudick1, Chris Polman, David Clifford

  • 1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. rudickr@ccf.org

JAMA Neurology
|November 7, 2012
PubMed
Summary

Natalizumab, a multiple sclerosis treatment, faced a temporary suspension due to safety concerns but was reapproved. Advanced risk management strategies now enable safer clinical use for patients.

More Related Videos

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

7.2K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.3K

Related Experiment Videos

Last Updated: May 5, 2026

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
08:05

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

Published on: March 1, 2017

8.8K
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

7.2K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.3K

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Clinical Neurology

Background:

  • Natalizumab is a biologic therapy approved for multiple sclerosis (MS).
  • Its development timeline from target discovery to FDA approval was rapid.
  • Post-approval safety concerns led to a temporary market withdrawal.

Purpose of the Study:

  • To review the historical trajectory of natalizumab.
  • To examine its regulatory journey, including approval, suspension, and reintroduction.
  • To discuss the evolution of its clinical application and safety management.

Main Methods:

  • Literature review of natalizumab's development and clinical use.
  • Analysis of regulatory actions and safety data.
  • Synthesis of information on risk stratification and management strategies.

Main Results:

  • Natalizumab was approved in 2004, suspended shortly after due to progressive multifocal leukoencephalopathy (PML) cases, and reapproved in 2006.
  • Over 92,000 patients have since been treated.
  • Development of risk algorithms and PML management strategies has improved safety.

Conclusions:

  • The natalizumab case illustrates the complexities of novel biologic therapies for progressive neurological diseases.
  • Balancing therapeutic benefits with safety risks is crucial.
  • Ongoing pharmacovigilance and risk management are essential for long-term safe use.